CELU
CELU clinical trials: Celularity Inc
Every trial on ClinicalTrials.gov where Celularity Inc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 17
- Trials linked
- 17
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CELU on the catalyst calendar · CELU registry changes
- Primary completion Feb 2012ActualPhase 2NCT01155362PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's DiseaseCelularity Incorporated · Crohn's DiseaseCompletedCELULeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2021ActualPhase 1/Phase 2NCT05218408CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild TypeCelularity Incorporated · Astrocytoma, Grade IVWithdrawnCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2021ActualPhase 1/Phase 2NCT04365101Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19Celularity Incorporated · CoronavirusTerminatedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 27, 2018ActualPhase 2NCT02264288Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.Celularity Incorporated · Peripheral Arterial DiseaseTerminatedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2016ActualPhase 1NCT01859117Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot UlcersCelularity Incorporated · Peripheral Arterial DiseaseCompletedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2016ActualPhase 2NCT02460081Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial DiseaseCelularity Incorporated · Diabetic FootWithdrawnCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2024ActualPhase 1/Phase 2NCT05207722CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive...Celularity Incorporated · Metastatic HER2 Positive Gastroesophageal Junction CancerTerminatedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 20, 2023ActualPhase 1NCT04310592Natural Killer Cell (CYNK-001) Infusions in Adults with AMLCelularity Incorporated · LeukemiaTerminatedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2023ActualPhase 1NCT04309084Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple MyelomaCelularity Incorporated · Multiple MyelomaUnknown statusCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 10, 2021ActualPhase 1NCT04489420Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBMCelularity Incorporated · Astrocytoma, Grade IVTerminatedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 7, 2017ActualPhase 2NCT02552277A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral...Celularity Incorporated · Diabetic NephropathiesCompletedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 10, 2018ActualPhase 1NCT02955550A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous...Celularity Incorporated · Multiple MyelomaCompletedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2017ActualPhase 1NCT02781467A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human...Celularity Incorporated · Leukemia, Myeloid, AcuteTerminatedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2012ActualPhase 2NCT01261403Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid ArthritisCelularity Incorporated · Rheumatoid ArthritisTerminatedCELULeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 1NCT01769755A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of...Celularity Incorporated · Crohns DiseaseCompletedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2014ActualPhase 1NCT01440192Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary...Celularity Incorporated · Stage 2 Pulmonary SarcoidosisTerminatedCELULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2013ActualPhase 2NCT01310114Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic StrokeCelularity Incorporated · Stroke, AcuteTerminatedCELULeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner